Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maraviroc Add-On Therapy for Steatohepatitis in HIV – The MASH Study
2017-003172-32Phase 2Terminated
- Sponsor
- Imperial College London
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of aprepitant in metabolic dysfunction-associated steatohepatitis (MASH) and human immunodeficiency virus infection (HIV), sponsored by Imperial College London. Primary endpoint: Change in hepatic immune cells. Started Feb 2018; status: terminated.
02
Drugs
aprepitant
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2017-003172-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003172-32.